Document Detail

Cyclosporin A in marrow transplantation for leukemia and aplastic anemia.
MedLine Citation:
PMID:  3886417     Owner:  NLM     Status:  MEDLINE    
A total of 29 consecutive patients with leukemia or aplastic anemia who received an HLA-identical marrow graft were given cyclosporin A (CyA) to prevent graft-versus-host disease (GvHD). These patients were compared with an historic group of 25 similar patients with leukemia or AA given methotrexate (MTX) for GvHD prophylaxis at this institution. Engraftment was faster in patients given CyA when compared with MTX patients, with less days of granulocytopenia (P = 0.04), a shorter interval before reaching a platelet count of 70 X 10(9)/l (P = 0.04), fewer major infections (P = 0.01), and fewer days on intravenous antibiotics (P = 0.02). There were no graft failures in CyA patients compared with four of 25 in MTX patients (P = 0.01). Early mortality was lower in CyA patients but not significantly (P = 0.06). The incidence of pulmonary complications was comparable, five of 29 and seven of 25 in CyA and MTX patients, respectively, but the clinical features of such complications differed. Interstitial pneumonia developing after day 30 was seen in MTX patients, whereas an acute respiratory distress syndrome developing between day +8 and day +18 was seen in CyA patients. Acute GvHD was less severe in CyA patients (P = 0.04), but chronic GvHD was comparable (P = 0.3). The actual one-year survival is currently 72% and 52% in CyA and MTX patients, respectively (P = 0.1). Although our initial experience with CyA is encouraging with regard to engraftment and acute GvHD, optimization of CyA protocols will probably be needed for it to be proven as having a definite advantage over MTX.
A Bacigalupo; F Frassoni; M T van Lint; M R Raffo; V Vitale; G Corbetta; S Chierichetti; A M Marmont
Related Documents :
18983417 - Micafungin alone or in combination with other systemic antifungal therapies in hematopo...
8065157 - Bone marrow cellularity in myeloid stem cell disorders: impact of age correction.
11480557 - Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid l...
18095887 - Targeted therapy in chronic myeloid leukemia.
1472927 - Glycosylated serum ferritin in patients with hematological malignancies before and afte...
23272527 - Importance of posture assessment in ankylosing spondylitis. preliminary study.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Experimental hematology     Volume:  13     ISSN:  0301-472X     ISO Abbreviation:  Exp. Hematol.     Publication Date:  1985 May 
Date Detail:
Created Date:  1985-05-30     Completed Date:  1985-05-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0402313     Medline TA:  Exp Hematol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  244-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Aplastic / therapy*
Bone Marrow Transplantation*
Child, Preschool
Cyclosporins / adverse effects,  therapeutic use*
Graft vs Host Disease / prevention & control
Hirsutism / chemically induced
Kidney / drug effects
Leukemia / therapy*
Liver / drug effects
Lung Diseases / etiology
Methotrexate / therapeutic use
Nausea / chemically induced
Tremor / chemically induced
Vomiting / chemically induced
Reg. No./Substance:
0/Cyclosporins; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Muscular exercise in type I-diabetics. II. Hormonal and metabolic responses to moderate exercise.
Next Document:  Autologous marrow transplantation in patients with acute nonlymphocytic leukemia in first remission.